Marius Pharmaceuticals Strengthens IP Portfolio with New KYZATREX® (testosterone undecanoate) CIII Capsules Formulation Patent
This marks Marius Pharmaceuticals’ fifth U.S. patent, further reinforcing its leadership in the field of testosterone replacement therapy. The newly allowed patent specifically covers the company’s ...
Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug
Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...
BioSpace1h
Merck Commits Nearly $2B for Oral Lipid-Lowering Drug from Chinese Biotech
Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...
Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui
Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...
Carlsbad’s Ionis strikes deal with Japanese pharma worth up to $940M
Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...
CNS Pharma Shares Sink After Berubicin Trial for Brain Cancer Misses Survival Endpoint
CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, ...
Moleculin biotech highlights pivotal Phase 3 trials for Annamycin in AML with interim results expected in 2025
Discover how Moleculin Biotech advances Annamycin's Phase 3 trial for AML treatment, with key milestones planned through 2025.
pharmaphorum14h
Pharma’s climate change vulnerability and opportunity
Pharma companies are “highly vulnerable” to the effects of climate change, due to their reliance on global networks. “The pharmaceutical industry is globalized: generic drugs manufactured at ...